نمایش پرونده ساده آیتم

dc.contributor.authorKhoei, NS
dc.contributor.authorAtashpaz, S
dc.contributor.authorGhabili, K
dc.contributor.authorKhoei, NS
dc.contributor.authorOmidi, Y
dc.date.accessioned2018-08-26T09:01:19Z
dc.date.available2018-08-26T09:01:19Z
dc.date.issued2009
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54993
dc.description.abstractMultiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Among the numerous proposed etiologies, Borrelia burgdorferi (a causative agent of Lyme disease) has been associated with MS. Although the current MS therapies decrease the quantity and severity of the attacks, most patients experience various neurologic symptoms obliging them to have recourse to one or more com-plementary and alternative medicines along with the conventional medical interventions. Among these, bee venom (BV) therapy is increasingly used for the treatment of MS; nonetheless no animal or human studies have so far revealed an improvement in the symptoms of MS upon such therapy. Herein, the authors discuss the plausible factors giving rise to the inefficacy of BV in amelioration of MS symptoms, despite its highly anti-inflammatory properties. We hypothesize that BV compound purified of phospholipase A2 that highly contains melittin and hyaluronidase may alleviate the symptoms of MS, directly through anti-inflammatory effects and degradation of hyaluronan accumulated in inflammatory demyelinating lesions, and indirectly by inhibitory effects on Borrelia burgdorferi. Thus, upon this hypothesis, we suggest that the melittin and hyaluronidase be injected into specific trigger points in the patients diagnosed with MS in randomized clinical trials to assess the efficacy of the proposed modality. آ© 2009 Nazaninalsadat Seyed Khoei et al.
dc.language.isoEnglish
dc.relation.ispartofIranian Journal of Medical Hypotheses and Ideas
dc.subjectautoantibody
dc.subjectbee venom
dc.subjectcytokine
dc.subjectgadolinium
dc.subjectgamma interferon
dc.subjecthyaluronic acid
dc.subjecthyaluronidase
dc.subjectmelittin
dc.subjectmyelin basic protein
dc.subjectmyelin oligodendrocyte glycoprotein
dc.subjectphospholipase A2
dc.subjecttumor necrosis factor alpha
dc.subjectacupuncture
dc.subjectantibacterial activity
dc.subjectantiinflammatory activity
dc.subjectarticle
dc.subjectbioaccumulation
dc.subjectBorrelia burgdorferi
dc.subjectCD4+ T lymphocyte
dc.subjectCD8+ T lymphocyte
dc.subjectclinical feature
dc.subjectcontrast enhancement
dc.subjectdisease association
dc.subjectdisease course
dc.subjectdisease severity
dc.subjectdrug effect
dc.subjectdrug mechanism
dc.subjectenzyme purification
dc.subjectglycosaminoglycan metabolism
dc.subjecthuman
dc.subjectimmunomodulation
dc.subjectimmunopathogenesis
dc.subjectmultiple sclerosis
dc.subjectnonhuman
dc.subjectnuclear magnetic resonance imaging
dc.subjectoutcome assessment
dc.titleMelittin and hyaluronidase compound derived from bee venom for the treatment of multiple sclerosis
dc.typeArticle
dc.citation.volume3
dc.citation.issue1
dc.citation.indexScopus


فایلهای درون آیتم

Thumbnail

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم